{"id":"adt","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Erectile dysfunction"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Bone loss / osteoporosis"},{"rate":null,"effect":"Metabolic syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADT works by reducing circulating testosterone levels through chemical or surgical castration, thereby inhibiting androgen-dependent prostate cancer cell growth. This approach is standard in advanced prostate cancer management, often combined with other agents like androgen receptor antagonists to achieve maximal androgen blockade.","oneSentence":"ADT is an androgen deprivation therapy regimen used in prostate cancer treatment to suppress testosterone production and androgen receptor signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:06.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Metastatic castration-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT06592924","phase":"PHASE3","title":"Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-05-28","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":830},{"nctId":"NCT04705038","phase":"NA","title":"Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-12-18","conditions":"Prostate Cancer","enrollment":101},{"nctId":"NCT05826509","phase":"PHASE2","title":"SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-08-10","conditions":"Prostate Cancer","enrollment":240},{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT06235697","phase":"PHASE3","title":"Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-25","conditions":"Prostate Cancer","enrollment":710},{"nctId":"NCT05931419","phase":"","title":"High-Risk prostatE Cancer radiatiOn Versus surgERy","status":"RECRUITING","sponsor":"Comprehensive Cancer Centre The Netherlands","startDate":"2023-02-16","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":837},{"nctId":"NCT05328505","phase":"NA","title":"Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-08-23","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT07490210","phase":"PHASE2","title":"Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-05-01","conditions":"Oligometastatic Prostate Cancer","enrollment":300},{"nctId":"NCT05939414","phase":"PHASE3","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-12","conditions":"Oligometastatic Prostate Cancer (OMPC)","enrollment":450},{"nctId":"NCT07426094","phase":"PHASE2, PHASE3","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1600},{"nctId":"NCT06282185","phase":"NA","title":"SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy","status":"WITHDRAWN","sponsor":"Canisius-Wilhelmina Hospital","startDate":"2024-11-01","conditions":"Prostatic Neoplasms, Metastasis","enrollment":""},{"nctId":"NCT05096338","phase":"","title":"Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-10-27","conditions":"Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions","enrollment":200},{"nctId":"NCT07426055","phase":"PHASE2, PHASE3","title":"PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1200},{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-15","conditions":"Prostatic Neoplasms","enrollment":469},{"nctId":"NCT07462403","phase":"NA","title":"A mLifestyle Intervention for Men on Androgen Deprivation Therapy for PCa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-05-02","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT02722525","phase":"NA","title":"Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2014-12","conditions":"Cardiovascular Injury, Prostate Carcinoma","enrollment":23},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT05477823","phase":"EARLY_PHASE1","title":"Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-08","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis","enrollment":100},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT07483658","phase":"NA","title":"Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.","status":"NOT_YET_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2026-02","conditions":"Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer","enrollment":434},{"nctId":"NCT05348876","phase":"PHASE4","title":"A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-08-03","conditions":"Non-metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT07476677","phase":"PHASE2","title":"Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-04-01","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT07476001","phase":"PHASE2","title":"Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":12},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT03274687","phase":"PHASE3","title":"Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-07-28","conditions":"Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7","enrollment":296},{"nctId":"NCT04037254","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2019-10-08","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":22},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":"Prostatic Neoplasms","enrollment":75},{"nctId":"NCT07335796","phase":"PHASE2","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-09","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT07463092","phase":"NA","title":"Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2026-03","conditions":"Prostate Cancer, Sarcopenia","enrollment":34},{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT06654336","phase":"PHASE2","title":"Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)","status":"RECRUITING","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2026-03-30","conditions":"Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer","enrollment":162},{"nctId":"NCT05901649","phase":"","title":"A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2023-07-05","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":504},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT05361798","phase":"PHASE2","title":"T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-12","conditions":"Cancer Of Prostate","enrollment":65},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06040125","phase":"NA","title":"Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-01","conditions":"PROSTATE CANCER, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma","enrollment":80},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Prostatic Neoplasms","enrollment":1145},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT07460726","phase":"","title":"PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"CancerCare Manitoba","startDate":"2026-03-16","conditions":"Prostate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction Male","enrollment":130},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":"Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer","enrollment":33},{"nctId":"NCT06957691","phase":"PHASE2","title":"Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"Shehzad Basaria, M.D.","startDate":"2026-01-14","conditions":"Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease","enrollment":60},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT02946996","phase":"PHASE2","title":"Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2016-12-28","conditions":"Prostate Cancer","enrollment":41},{"nctId":"NCT06130995","phase":"PHASE1","title":"Relugolix + Enzalutamide Study in High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":"Androgen Deprivation Therapy, Locally Advanced Prostate Cancer","enrollment":46},{"nctId":"NCT07450599","phase":"PHASE2","title":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-15","conditions":"High-Risk Localized Prostate Cancer","enrollment":250},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":"Prostatic Neoplasms","enrollment":10},{"nctId":"NCT06171269","phase":"NA","title":"Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-01-05","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT06931340","phase":"PHASE3","title":"Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-12-01","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":1260},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT03938649","phase":"PHASE2","title":"SRAM study_Postate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2019-05-15","conditions":"Advanced Prostate Cancer","enrollment":120},{"nctId":"NCT02997709","phase":"","title":"Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients","status":"RECRUITING","sponsor":"University of Miami","startDate":"2016-06-24","conditions":"Prostate Cancer","enrollment":144},{"nctId":"NCT07444983","phase":"NA","title":"Rezvilutamide for High-Risk Prostate Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2026-02-11","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":33},{"nctId":"NCT01409200","phase":"PHASE2","title":"Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03-26","conditions":"Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":73},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT05676463","phase":"PHASE2","title":"MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2022-11-16","conditions":"Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8","enrollment":6},{"nctId":"NCT07224009","phase":"PHASE2","title":"Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-03","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT06237179","phase":"PHASE1, PHASE2","title":"Behavioral Exercise Training to Reduce Cardiovascular Disease Risk","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2024-02-21","conditions":"Prostate Cancer, Supportive Care","enrollment":60},{"nctId":"NCT07206056","phase":"PHASE1, PHASE2","title":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-10-15","conditions":"Progressive Metastatic Castrate Resistant Prostate Cancer","enrollment":188},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT04443062","phase":"PHASE2","title":"Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-07-20","conditions":"Prostate Cancer","enrollment":58},{"nctId":"NCT04943536","phase":"PHASE1","title":"Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alessa Therapeutics Inc.","startDate":"2021-12-07","conditions":"Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT05879913","phase":"NA","title":"ASCVD Management Using CCTA in Prostate Cancer Patients on ADT","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-12-15","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT02296229","phase":"NA","title":"Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2014-01-27","conditions":"Adenocarcinoma of the Prostate, Stage III Prostate Cancer","enrollment":220},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT05820932","phase":"","title":"Predicting Cognitive Decline From Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-05-22","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT03388619","phase":"PHASE1","title":"Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-17","conditions":"Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer","enrollment":30},{"nctId":"NCT01410942","phase":"PHASE2","title":"Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-08","conditions":"Prostate Cancer","enrollment":175},{"nctId":"NCT05720130","phase":"PHASE1, PHASE2","title":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","status":"RECRUITING","sponsor":"AdvanCell Pty Limited","startDate":"2023-03-15","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":100},{"nctId":"NCT04947254","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-05","conditions":"Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":200},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT05593029","phase":"PHASE2","title":"A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-09","conditions":"Major Depressive Disorder","enrollment":929},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT04725903","phase":"NA","title":"Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-02-01","conditions":"Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT06724159","phase":"","title":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2024-12-13","conditions":"Genitourinary Cancers","enrollment":500},{"nctId":"NCT04983095","phase":"NA","title":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Karin Soderkvist","startDate":"2021-10-27","conditions":"Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography","enrollment":118},{"nctId":"NCT07395804","phase":"","title":"How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-28","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":500},{"nctId":"NCT04316650","phase":"NA","title":"Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06","conditions":"Paraphilia","enrollment":""},{"nctId":"NCT07406282","phase":"","title":"A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-07-22","conditions":"Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1400},{"nctId":"NCT01517451","phase":"PHASE1, PHASE2","title":"Radiation and Androgen Ablation for Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-05-22","conditions":"Adenocarcinoma of the Prostate","enrollment":45},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":"Prostate Cancer","enrollment":144},{"nctId":"NCT03624660","phase":"PHASE2","title":"Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-09-24","conditions":"Adenocarcinoma of the Prostate","enrollment":100},{"nctId":"NCT05059236","phase":"PHASE2","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-11-04","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":223},{"nctId":"NCT07393880","phase":"NA","title":"Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus","status":"RECRUITING","sponsor":"University of Dublin, Trinity College","startDate":"2026-01-30","conditions":"Tinnitus, Subjective, Tinnitus, Chronic Tinnitus","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":13,"reaction":"DIZZINESS"},{"count":11,"reaction":"NAUSEA"},{"count":9,"reaction":"PALPITATIONS"},{"count":8,"reaction":"MALAISE"},{"count":7,"reaction":"HYPOAESTHESIA"},{"count":6,"reaction":"DIARRHOEA"},{"count":5,"reaction":"HEADACHE"},{"count":4,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":4,"reaction":"GAMMA-GLUTAMYLTRANSFERASE INCREASED"},{"count":4,"reaction":"MALIGNANT NEOPLASM PROGRESSION"}],"_approvalHistory":[],"publicationCount":7395,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Androgen Deprivation Therapy","Goserelin","FDA Approved Antidepressant (ADT)","Lupron or Zoladex","Hormone Therapy"],"phase":"phase_3","status":"active","brandName":"ADT","genericName":"ADT","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADT is an androgen deprivation therapy regimen used in prostate cancer treatment to suppress testosterone production and androgen receptor signaling. Used for Advanced prostate cancer, Metastatic castration-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}